HE8
0.002
100%
KNI
0.02
-25.9%
COY
0.005
66.7%
SNT
0.027
-22.9%
BSN
0.033
50%
ARF
2.56
-22%
OVT
0.003
50%
ITS
0.21
-20.8%
TMX
0.003
50%
SLM
0.068
-20%
WOA
0.014
40%
HCT
0.055
-17.9%
RIM
0.015
36.4%
BNL
0.005
-16.7%
ARO
0.004
33.3%
CLA
0.005
-16.7%
BET
0.22
33.3%
FCT
0.005
-16.7%
BLU
0.004
33.3%
H3E
0.005
-16.7%
PER
0.004
33.3%
REE
0.01
-16.7%
AVH
2.03
31.8%
YAR
0.005
-16.7%
EVG
0.028
27.3%
JAT
0.11
-15.4%
FRE
0.033
26.9%
PKO
0.006
-14.3%
FLN
0.145
26.1%
XRA
0.19
-13.6%
ENL
0.005
25%
MDI
0.013
-13.3%
L1M
0.015
25%
CNJ
0.007
-12.5%
HMI
0.034
21.4%
T92
0.038
-11.6%
RB6
0.115
21.1%
ATT
0.008
-11.1%
PHO
0.145
20.8%
DUB
0.008
-11.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

LTR Pharma (ASX:LTP) has listed on the ASX

LTR Pharma (ASX:LTP) has listed on the ASX with a ticker code of LTP. The company is a clinical stage biopharmaceutical company and pioneering a novel intranasal technology – SPONTAN® – designed to treat erectile dysfunction in 10 minutes or less. LTR Pharma says the benefit of its business model is a significantly reduced time to approval and lower cost, even when compared with traditional drug repurposing strategies. The global erectile dysfunction market is expected to generate revenue of more than $7 billion US dollars by the end of 2026 | Investor presentation: https://lnkd.in/gb3b5T3j #LTP #ASX #ASXstocks #stocks #ASXIPO ##LTRPharma #ED #erectiledysfunction #shorts